financetom
Business
financetom
/
Business
/
U.S. Bancorp to Increase Quarterly Dividend Following Federal Reserve's 2024 Stress Test Results
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
U.S. Bancorp to Increase Quarterly Dividend Following Federal Reserve's 2024 Stress Test Results
Jul 1, 2024 3:50 AM

06:39 AM EDT, 07/01/2024 (MT Newswires) -- U.S. Bancorp ( USB ) said Friday it plans to increase in Q4 its quarterly dividend to $0.50 per share, from $0.49 previously, following the results of the Federal Reserve's 2024 Dodd-Frank Act Stress Test.

The company said it expects a preliminary stress capital buffer requirement of 3.1% for the period beginning Oct. 1 through Sept. 30, 2025 based on the stress test.

The Federal Reserve is expected to finalize the SCB for all firms by the end of August, according to U.S. Bancorp ( USB ).

Given the preliminary SCB, Basel III rules would require the company to maintain a common equity tier 1 ratio of at least 7.6% during the period, U.S. Bancorp ( USB ) said.

In a report released last week, the Federal Reserve projected U.S. Bancorp ( USB ) to reach a minimum CET1 ratio of 7.5% under a severely adverse stress test scenario for Q1 2024 through Q1 2026. The required minimum is 4.5%.

U.S. Bancorp ( USB ) said it estimates its CET1 capital to risk-weighted assets ratio to be 10% as of March 31 this year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Swedish fintech Klarna shares open 30% above IPO price in NYSE debut
Swedish fintech Klarna shares open 30% above IPO price in NYSE debut
Sep 10, 2025
Sept 10 (Reuters) - Shares of Klarna ( KLAR ) opened 30% above their offer price in their New York Stock Exchange debut on Wednesday, giving the Swedish fintech a valuation of $19.65 billion. (Reporting by Arasu Kannagi Basil and Pritam Biswas in Bengaluru) ...
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
US tariffs, pricing risks to be manageable for Big Pharma, Morningstar says
Sep 10, 2025
(Reuters) -The impact of U.S. President Donald Trump's plan to levy import duties on pharmaceutical products and his push to lower drug prices are likely to be manageable for big U.S. and European drugmakers, according to an analysis by brokerage Morningstar. The report said the near term risk from the push to slash prescription drug prices to match those paid...
Prinses Máxima Center for Pediatric Oncology Implements Callisto™ from Volta Labs to Streamline Clinical Genomics Workflows
Prinses Máxima Center for Pediatric Oncology Implements Callisto™ from Volta Labs to Streamline Clinical Genomics Workflows
Sep 10, 2025
BOSTON, Sept. 10, 2025 /PRNewswire/ -- Volta Labs today announced that the Prinses Máxima Center for Pediatric Oncology has acquired the Callisto™ platform to streamline sample preparation across multiple genomics workflows, supporting both Illumina and Oxford Nanopore Technologies (ONT) sequencing platforms. The Prinses Máxima Center is the largest pediatric cancer center in Europe, dedicated to integrating care and research to...
Kering delays full Valentino acquisition to 2028 amid debt concerns
Kering delays full Valentino acquisition to 2028 amid debt concerns
Sep 10, 2025
PARIS (Reuters) - Kering said on Wednesday that it will not fully buy Italian fashion brand Valentino until at least 2028, its first major move under new CEO Luca de Meo, pushing back the execution of an expensive deal that has been weighing on the heavily indebted group. The deal - announced just a day after de Meo was charged...
Copyright 2023-2026 - www.financetom.com All Rights Reserved